Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Jun 9;18(6):e0287043. doi: 10.1371/journal.pone.0287043

Multidrug-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated from chicken droppings in poultry farms at Gondar City, Northwest Ethiopia

Mitkie Tigabie 1,*, Sirak Biset 1, Teshome Belachew 1, Azanaw Amare 1, Feleke Moges 1
Editor: Md Tanvir Rahman2
PMCID: PMC10256222  PMID: 37294782

Abstract

Background

The poultry sector is one of the largest and fastest-growing agricultural sub-sector, especially in developing countries like Ethiopia. In poultry production, poultry farmers use sub-optimum doses of antibiotics for growth promotion and disease prevention purpose. This indiscriminate use of antibiotics in poultry farms contributes to the emergence of antibiotic-resistant bacteria, which has adverse implications for public health. Therefore, this study is aimed to assess multidrug resistance and extended-spectrum beta-lactamase-producing Enterobacteriaceae from chicken droppings in poultry farms.

Methods

A total of 87 pooled chicken-dropping samples were collected from poultry farms from March to June 2022. Samples were transported with buffered peptone water. Selenite F broth was used for the enrichment and isolation of Salmonella spp. Isolates were cultured and identified by using MacConkey agar, Xylose lysine deoxycholate agar, and routine biochemical tests. Kirby-Bauer disk diffusion technique and combination disk test were used for antibiotic susceptibility testing and confirmation of extended-spectrum beta-lactamase production, respectively. Data were entered using Epi-data version 4.6 and then exported to SPSS version 26 for analysis.

Result

Out of 87 pooled chicken droppings, 143 Enterobacteriaceae isolates were identified. Of these, E. coli accounts for 87 (60.8%), followed by Salmonella spp. 23 (16.1%), P. mirabilis 18 (12.6%) and K. pneumoniae 11 (7.7%). A high resistance rate was observed for ampicillin 131 (91.6%), followed by tetracycline 130 (90.9), and trimethoprim-sulfamethoxazole 94 (65.7%). The overall multidrug resistance rate was 116/143 (81.1%; 95% CI: 74.7–87.5). A total of 12/143 (8.4%; CI: 3.9–12.9) isolates were extended-spectrum beta-lactamase producers, with 11/87 (12.6%) E. coli and 1/11 (9.1%) K. pneumoniae.

Conclusion and recommendations

High prevalence of multi-drug resistant isolates was observed. This study alarms poultry as a potential reservoir of extended-spectrum beta-lactamase-producing Enterobacteriaceae, which might shed and contaminate the environment through faecal matter. Prudent use of antibiotics should be implemented to manage antibiotic resistance in poultry production.

Introduction

Poultry is one of the most widespread food animals and chicken is the largest farmed animal species worldwide [1]. The poultry sector is one of the largest and fastest-growing agricultural sub-sector, especially in developing countries like Ethiopia. It is an essential component of the country’s economy, providing income for farmers and a good source of high-quality protein for the ever-growing population of Ethiopia [2]. However, in the poultry sector, in addition to using antibiotics for therapy and disease prevention, antibiotics are regularly added to poultry feed in sub-therapeutic doses for growth promotion [3].

Globally, over 50% of antibiotics are used by the food animal industry and an increase of 50% in antibiotic usage for farming is estimated by 2030 [4]. An estimated 25 million pounds of antimicrobials are used for non-therapeutic purposes in chickens, pigs, and cows, while only 3 million pounds are used for human medicine worldwide [5].

Developed countries have implemented prudent antibiotic use policies and surveillance systems both in clinical and veterinary settings. There are no such systems in low and middle-income countries [3]. In these countries, antibiotics are used in poultry for three main reasons: 1) Poultry flock treatment when illness is first recognized in a small proportion of the chickens; 2) to prevent diseases when the physical stress involved in the movement of chickens in large numbers; and 3) as a growth promoter to boost chickens weight [6, 7].

The irrational use of antibiotics in poultry farms for growth promotion and disease prevention triggers high selection pressure among bacterial agents, which might contribute to the emergence and development of antibiotic-resistant (ABR) bacteria [8]. Antibiotic resistance increases time-to-time. It has been declared by World Health Organization as one of the top ten global public health threats in the 21st century [9]. Currently, an estimated 700,000 people a year die of ABR infections in the globe. If action is not taken, this number could rise to around 10 million per year, with a global loss of 100 trillion United States dollars by 2050 [10]. More than 2.8 million ABR occur, resulting in more than 35,000 deaths annually in the United States alone [11]. In Africa, approximately 4.2 million deaths also occur annually due to ABR [10].

Extended-spectrum beta-lactamase (ESBL) genes have led to the emergence of bacteria that are resistant to most antibiotics [12]. Extended-spectrum beta-lactamase is an enzyme that can hydrolyze penicillin, cephalosporins, and aztreonam and is inhibited by beta-lactamase inhibitors, like clavulanic acid [13]. The most common ESBL types found in poultry and poultry products are CTX-M-1, TEM-52 and SHV-12. Extended-spectrum beta-lactamase-producing bacteria are also, present in every type of commercial chicken and can be detected even in newly hatched chickens. This enzyme is most common in gram-negative bacteria, particularly in Enterobacteriaceae such as Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) [12]. Some of these bacteria are significant causes of foodborne, urinary tract, respiratory tract, bloodstream, and wound infections in humans [14].

Extended-spectrum beta-lactamase-producing bacteria in the poultry sector are recognized as a potential community health concern. Because, it can be transmitted through food chains, in close contact with poultry, leafy vegetables and via bodies of water contaminated with poultry droppings. So, it is very important to monitor the resistance to antibiotics not only in human bacterial pathogens but also in pathogenic and commensal bacteria of poultry origin [1517].

Awareness of the prevalence of ABR in poultry provides baseline data to implement an integrated ABR surveillance system and also facilitates the evaluation of interventions used to control the ABR. Monitoring and surveillance of ABR at poultry farms may help to reduce the transfer of ABR bacteria from poultry to humans directly or indirectly through the environment [18]. In Ethiopia, Multidrug resistance has not been well-studied and extended-spectrum beta-lactamase-producing Enterobacteriaceae from poultry droppings are still missing, particularly in Northwest Ethiopia. Therefore, this study is aimed to determine the multidrug resistance (MDR) and ESBL-producing Enterobacteriaceae from chicken droppings in poultry farms at Gondar City, Northwest Ethiopia.

Materials and methods

Study design, period, and area

A survey was conducted from March 1, 2022, to June 30, 2022. The study was conducted in Gondar City Ethiopia. Gondar is one of the ancient historical cities in Ethiopia and is located 737 Km from Addis Ababa, the country’s capital. The city’s total population is estimated to be 395,138 [19]. According to the information obtained from Gondar city’s rural and urban agriculture centre, 87 poultry farms supply chickens and eggs to the society.

Data collection and analysis

Data related to general characteristics and antibiotic use in the poultry farms were collected by face-to-face interview technique from the chicken caregivers or owners using a semi-structured questionnaire before sample collection. All data were collected and analyzed by a trained laboratory technologist.

Sample collection, transportation, processing, and identification

A total of 87 chicken-dropping samples were randomly collected from poultry farms. A sample consisted of a pool of five fresh chicken droppings obtained from the five different parts of the poultry building [20].

Each farm was visited once, and the samples were collected using sterile applicator sticks and stored in sterile universal sampling bottles containing 90 ml buffer peptone water (BPW) (Himedia, India M614). A code was attributed to each universal sampling bottle and placed in a cooler (icebox) containing ice packs. Immediately, samples were transported to the School of Biomedical and Laboratory Sciences, Medical Microbiology laboratory section.

After homogenization, about 1 millilitre of the sample was further transferred into two different test tubes containing 9 ml of BPW (Himedia, India, M614) and 5 ml of selenite F broth (Himedia, India M414). Test tubes were incubated at 37°C for 18–24 hrs. After incubation, samples from BPW were streaked on a MacConkey agar plate (Oxoid Ltd, Basingstoke, United Kingdom (UK)). Samples from selenite F broth were streaked on a xylose lysine deoxycholate agar plate (XLD) (HiMedia, India, M608) [21]. All the plates were incubated aerobically at 37°C for 24 hrs.

At the end of incubation, the MacConkey and XLD agar plates were examined for growth and preliminary identification of the bacteria was done based on the characteristics of the bacteria colony (size, shape, colour, texture, elevation, edge). In addition, the smear was prepared from each colony observed on the plates and gram staining was performed. The gram reaction and the shape of the bacteria were observed using a microscope.

After the identification of gram-negative bacteria, a series of biochemical tests were performed on colonies from pure cultures of the isolates. Triple sugar iron agar (TSI) (Oxoid Ltd, Basingstoke UK), Simon’s citrate agar (Oxoid Ltd, Basingstoke, UK), urease agar (Oxoid Ltd, Basingstoke, UK), lysine iron agar (Oxoid Ltd, Basingstoke, UK) (LDC), and Sulphur indole motility medium (SIM) (Oxoid Ltd, Basingstoke, UK) were included in the biochemical tests for species identification [22].

Antibiotic susceptibility testing

Following bacterial identification, the antibiotic susceptibility testing (AST) of the isolates was performed by a Kirby-Bauer disk diffusion technique. The colonies of a young culture were picked from the pure culture using a sterile wire loop and emulsified in 0.85% of normal saline to make bacterial suspension and compare with 0.5 McFarland turbidity standards. Then the bacterial suspension was inoculated onto Muller-Hinton agar (MHA) (Oxoid, Basingstoke, and Hampshire, UK) by lawn culture method. The AST was performed following the recommendation of the Clinical and Laboratory Standards Institute (CLSI) guideline 2021 against—ampicillin (10μ), gentamicin (10μg), tetracycline (30μg), nalidixic-acid [30] ciprofloxacin (5μg), chloramphenicol (30μg), trimethoprim-sulfamethoxazole (1.25μg/23.75μg), cefoxitin (30μg), cefotaxime (30μg), ceftazidime (30μg), ceftriaxone (30μg), and meropenem (10μg). All the antibiotic disks used were from BD, BBLTM Company, and USA Product. After overnight incubation at 37°C for 16–18 hours, the zone of inhibition was measured by a ruler and the results was interpreted as resistant, intermediate, and sensitive [23]. Bacterial isolates that were resistant to at least one antibiotic agent in three or more antibiotic classes were considered MDR isolates [24].

Detection of extended-spectrum beta-lactamase

All Enterobacteriaceae strains were tested against ceftriaxone, cefotaxime, and ceftazidime for ESBL screening using the Kirby-Bauer disk diffusion method. If the zone of inhibition was ≤ 22 mm for ceftazidime, ≤ 25 mm for ceftriaxone, and ≤ 27 for cefotaxime, they were considered as potential ESBLs-producing strains and selected for a further phenotypic confirmatory test as described below [23].

A phenotypic confirmatory test was done using a combined-disk diffusion test and interpreted by following the CLSI, 2021 guidelines. Pure culture of suspected ESBL producer isolates was emulsified in 0.85% saline and compared with 0.5 McFarland turbidity standard then inoculated on MHA by lawn culture method using sterile swabs. The following antibiotic disks such as cefotaxime (30μg), cefotaxime/clavulanic acid (30μg/10μg), ceftazidime (30μg), and ceftazidime/clavulanic acid (30μg/10μg) were used to confirm the status of the ESBL phenotypes. The plates were then incubated aerobically at 37°C for 16–18 hrs. If greater or equal to 5mm an increase in zone diameter for cefotaxime and ceftazidime in combination with clavulanic acid than the zone diameter of the tested alone, it was confirmed as ESBL-producing isolates [23].

Quality control

All culture media was prepared according to the manufacturer’s instructions and following standard operational procedures. The sterility of newly prepared culture media was checked by incubating 5% of prepared culture media at 35–37°C overnight before use and was evaluated for possible growth or contamination. The performance testing was performed with inoculating known control strains of E. coli American Type Culture Collection (ATCC) 25922 and Salmonella Typhimurium ATCC 14028 on culture media. For the ESBL confirmatory test, K. pneumoniae ATCC 700603 (ESBLs positive) and E. coli ATCC 25922 (ESBLs negative control) strains were used to check the quality of the culture media and antibiotic disks [23].

Data processing and analysis

All data were checked for completeness, coded, and entered using Epi-data version 4.6 and the data was exported to Statistical Package for Social Sciences version 26 for further analysis. Frequency analysis was carried out to determine the frequency of independent variables and the prevalence of MDR isolates. Fisher’s exact test was used to observe an appropriate association between independent variables and ESBL-producing isolates. A p-value of less than 0.05 at a 95% confidence interval in fisher’s exact test was considered an association between independent variables and ESBL-producing isolates. The results were presented in texts, figures, and tables.

Ethical approval

Ethical clearance was obtained from the Ethical Review Committee of the School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, the University of Gondar with protocol reference number SBMLS/202, dated 14 February 2022. The owner of each poultry farm was informed about the aim of the study and oral permission was obtained from the owners/ managers before sampling.

Results

General characteristics of the poultry farms

A total of 87 poultry farms were visited, and a farm owner or chicken caregiver was interviewed about the farm’s characteristics and how to handle the chickens. The majority of the poultry farms raised eggs layer chickens 55 (63.2%), used deep litter chicken housing systems 82 (94.3%), and used commercially prepared feeds 80 (92%). In most farms, 78 (89.7%) were not clean from chicken droppings and remained so until a new flock was introduced. In more than half of the poultry farms, diseased chickens weren’t isolated and separated. Almost all of the farm owners or the people who looked after the chickens had no profession related to the poultry industry (Table 1).

Table 1. General characteristics of the poultry farms at Gondar City, Northwest Ethiopia, March to June 2022.

Variables Category Frequency N (%) ESBL-status Fisher’s Exact test p-value
ESBL-positive ESBL- Negative
Type of commercial chicken Layer 55 (63.2) 10 (18.2) 45 (81.8) 0.129
Broiler 6 (6.9) 0 (0) 6 (100)
One day old 26 (29.9) 1 (3.8) 25 (96.2)
Flock size (number of chickens on the farm) <500 48 (55.2) 4 (8.3) 44 (91.7) 0.014*
500–1000 27 (31.0) 2 (7.4) 25 (92.6)
>1000 12 (13.8) 5 (41.7) 7(58.3)
Age of chicken (months) <2 34 (39.1) 6 (17.6) 28 (82.4) 0.037*
2–6 14 (16.1) 1 (7.1) 13 (92.9)
7–12 31 (35.6) 1(3.2) 30 (96.8)
>12 8 (9.2) 3 (37.5) 5 (62.5)
Farm age (years) <5 80 (92.0) 8 (10) 72 (90) 0.040*
5–10 7 (8.0 3 (42.9) 4 (57.1)
Chicken housing system Deep litter system 82 (94.3) 10 (12.2) 72 (87.8) 0.50
Traditional housing 5 (5.7) 1 (20) 4 (80)
Cleaning of chicken droppings When the flock changed (the flock out) 78 (89.7) 11 (14.1) 67 (85.9) 0.278
By six months per a year 9 (10.3) 0 (0.0) 9 (100)
Timely isolation and separation of diseased chickens Yes 35 (40.2) 8 (22.9) 27 (77.1) 0.024*
No 52 (59.8) 3 (5.8) 49 (94.2)
Professional short-term training is given Yes 81 (93.1) 10 (12.3) 71 (87.7) 0.567
No 6 (6.9) 1 (16.7) 5 (83.3)
Owners and chicken caregiver profession is related to the chicken farm Yes 4 (4.6) 1 (25.0) 3 (75.0) 0.424
No 83 (95.4) 10 (12.0) 73 (88.0)
Waste disposal Send to field 82 (94.3) 10 (12.2) 72 (87.) 0.500
Compost 5 (5.7) 1 (20.0) 4 (80.0)
Feeding condition Commercially prepared 80 (92.0) 11 (13.8) 69 (86.3) 0.588
Both commercially and locally prepared 7 (8.0) 0 (0.0) 7 (100)
Water source Well water 20 (23.0) 3 (15.0) 17 (85.0) 0.710
Pipe water 67 (77.0) 8 (11.9) 59 (88.1)
Chicken feeds contact with their droppings Yes 40 (46.0) 2 (5.0) 38 (95.0) 0.058
No 47 (54.0) 9 (19.1) 38 (80.9)

* Associations between independent variables and ESBL-producing isolates

Antibiotic use in the poultry farms

Of most poultry farmers 82 (94.3%) used antibiotics on their farms. Antibiotics given in poultry farms were enrofloxacin, oxytetracycline, ciprofloxacin, trimethoprim and sulphadiazine. The majority of poultry farms 75/82 (91.5%) used antibiotics for both preventive and treatment purposes. Out of antibiotic users, most of the poultry farmers purchased their antibiotics from a veterinary pharmacy and gave them to their chickens by mixing them with feed or water (Table 2).

Table 2. Type of antibiotics use in the poultry farms at Gondar City, Northwest Ethiopia, March to June 2022.

Variables Category Frequency N (%) ESBL-status Fisher’s Exact test p-value
ESBL-positive ESBL- Negative
Antibiotics use Yes 82 (94.3) 11 (13.4) 71(86.6) 1.00
No 5 (5.7) 0 (0.0) 5 (100)
Use of enrofloxacin Yes 68 (82.9) 11 (16.2) 57(83.8) 0.197
No 14 (17.1) 0 (0.0) 14 (100)
Use of oxytetracycline Yes 62 (75.6) 10 (16.1) 52 (83.9) 0.279
No 20 (24.4) 1 (5.0) 19 (95.0)
Use of trimethoprim and sulphadiazine Yes 14 (17.1) 5 (35.7) 9 (64.3 0.018*
No 68 (82.9) 6 (8.8) 62 (91.2)
Use of ciprofloxacin Yes 8 (9.8) 5 (62.5) 3 (37.5) 0.001*
No 74 (90.2) 6 (8.1) 68 (91.9)
Antibiotics used for treatment purposes Yes 71 (86.6) 11 (15.5) 60 (84.5) 0.345
No 11 (13.4) 0 (0.0) 11 (100)
Antibiotics used for prevention purposes Yes 4 (4.9) 0 (0.0) 4 (100) 1.00
No 78 (95.1) 11 (13.8) 67 (85.9)
Antibiotics are used for both prevention and treatment purposes Yes 75 (91.5) 11 (14.1) 64 (85.3) 0.586
No 7 (8.5) 0 (0.0) 7 (100)
Frequency of antibiotics use Regularly 8 (9.8) 1 (12.5) 7 (87.5) 1.00
Occasionally 74 (90.2) 10 (13.5) 64 (86.5)
Sources of antibiotics Veterinary drug store 73 (89) 7 (9.6) 66 (90.4) 0.016*
Parallel market 9 (11) 4 (44.4) 5 (55.6)
A common route of antibiotics administration Mixed with feed and/or water 76 (92.7) 11 (14.5) 65(85.5) 1.00
Injection or others 6 (7.3) 0 (0) 6 (100)

* Associations between independent variables and ESBL-producing isolates

Prevalence of Enterobacteriaceae isolates from chicken droppings

Among a total of 87 poultry farms chicken-dropping samples 143 bacterial isolates were recovered. Of these, the most common isolates were E. coli 87 (60.8%), followed by Salmonella spp. 23 (16.1%), P. mirabilis 18 (12.6%) and K. pneumoniae 11 (7.7%). E. coli 87 (100%) was recovered from all samples collected. However, Salmonella spp. were isolated in 23 (26.4%; 95% CI:17.2–35.6) and P. mirabilis in 18 (20.7%; 95% CI:12.6–28.7) samples (Fig 1).

Fig 1. The proportion of Enterobacteriaceae isolates from chicken droppings in poultry farms at Gondar City, Northwest Ethiopia, March to June 2022.

Fig 1

Antibiotic resistance patterns of Enterobacteriaceae

Out of 143 Enterobacteriaceae isolates, the highest resistance rate was observed for ampicillin 131 (91.6%) followed by tetracycline 130 (90.9), trimethoprim-sulfamethoxazole 94 (65.7%), and nalidixic acid 94 (65.7) and lowest resistance was observed against meropenem 13 (9.1%), gentamicin 16 (11.2%) and cefoxitin 24 (16.8%) (Table 3).

Table 3. Antibiotic resistance patterns of Enterobacteriaceae from chicken droppings in poultry farms at Gondar city, Northwest Ethiopia, March to June 2022.

Class Antibiotics E. coli Salmonella species P. mirabilis K. pneumoniae E. cloacae Total
N = 87 N = 23 N = 18 N = 11 N = 4 N = 143
S R S R S R S R S R S R
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Aminoglycosides GEN 78 (89.7) 9 (10.3) 22 (95.7) 1 (4.3) 15 (83.3) 3 (16.7) 9 (81.8) 2 (18.2) 3 (75.0) 1 (25.0) 127 (88.8) 16 (11.2)
Carbapenems MER 79 (90.8) 8 (9.2) 23 (100) - 15 (83.3) 3 (16.7) 9 (81.8) 2 (18.2) 4 (100) - 130 (90.9) 13 (9.1)
Cephalosporins CXT 76 (87.4) 11 (12.6) 21 (91.3) 2 (8.7) 13 (72.2) 5 (27.8) 8 (72.7) 3 (27.3) 1 (25.0) 3 (75.0) 119 (83.2) 24 (16.8)
CAZ 72 (82.8) 15 (17.2) 18 (78.3) 5 (21.7) 14 (77.8) 4 (22.2) 7 (63.6) 4 (36.4) 1 (25.0) 3 (75.0) 112 (78.3) 31 (21.7)
CRO 75 (86.2) 12 (13.8) 19 (82.6) 4 (17.4) 15 (83.3) 3 (16.7) 8 (72.7) 3 (27.3) 3 (75.0) 1 (25.0) 120 (83.9) 23 (16.1)
CTX 72 (82.8) 15 (17.2) 18 (78.3) 5 (21.7) 14 (77.8) 4 (22.2) 7 (63.6) 4 (36.4) 1 (25.0) 3 (75.0) 112 (78.3) 31 (21.7)
Quinolones NAL 28 (32.2) 59 (67.8) 11 (47.8) 12 (52.2) 5 (27.8) 13 (72.2) 4 (36.4) 7 (63.6) 1 (25.0) 3 (75.0) 49 (34.3) 94 (65.7)
CIP 68 (78.2) 19 (21.8) 20 (87.0) 3 (13.0) 7 (38.9) 11 (61.1) 8 (72.7) 3 (27.3) 2 (50.0) 2 (50.0) 105 (73.4) 38 (26.6)
Penicillin AMP 7 (8.0) 80 (92.0) 5 (21.7) 18 (78.3) - 18 (100) - 11 (100) - 4 (100) 12 (8.4) 131(91.6)
Phenicol CHL 62 (72.3) 25 (28.7) 21 (91.3) 2 (8.7) 10 (55.6) 8 (44.5) 6 (54.5) 5 (45.5) 3 (75.0) 1 (25.0) 102 (71.3) 41 (28.7)
Sulfonamides (folate pathway inhibitors) SXT 32 (36.8) 55 (63.2) 9 (39.1) 14 (60.9) 5 (27.8) 13 (72.2) 2 (18.2) 9 (81.8) 1 (25.0 3 (75.0) 49 (34.3) 94 (65.7)
Tetracycline TET 8 (9.2) 79 (90.8) 4 (17.4) 19 (82.6) - 18 (100) 1 (9.1) 10 (90.9) - 4 (100) 13 (9.1) 130 (90.9)

Key: S = Sensitive, R = Resistance, AMP = ampicillin; TET = tetracycline; SXT = trimethoprim-sulfamethoxazole; NAL = nalidixic acid; CHL = chloramphenicol; CIP = ciprofloxacin; CAZ = ceftazidime; CTX = cefotaxime, CRO = ceftriaxone; CXT = cefoxitin; GEN = gentamicin; MER = meropenem

Regarding the resistance rate of individual bacterial isolates, E. coli demonstrated a high rate of resistance against ampicillin 80/87 (92.0%), tetracycline 79/87 (90.8%), nalidixic acid 59/87 (67%), and trimethoprim-sulfamethoxazole 55/87 (63.2%). Likewise, K. pneumoniae isolates showed a high resistance rate against ampicillin 11/11 (100%), tetracycline 10/11 (90.9%), trimethoprim-sulfamethoxazole 9/11 (81.8%), and nalidixic acid 7/11 (63.6%). All isolates showed a lower resistance rate against meropenem and gentamicin, with a range of 9.2% to 18.2% and 4.3% to 25.0%, respectively.

Multi-drug resistant patterns of Enterobacteriaceae

A total of 12 antibiotics from 8 classes (aminoglycosides, amphenicol, carbapenems, cephalosporins, fluoroquinolones, folate pathway inhibitors, penicillin, and tetracycline) were used to assess the MDR patterns of isolates. The overall MDR prevalence in this study was 116/143 (81.1%; 95% CI: 74.7–87.5). The most common MDR isolates identified in this study were E. coli 73/87 (83.9%; 95% CI: 76.3–91.5) followed by K. pneumoniae 9/11 (81.8%; 95% CI: 69.1–94.5), P. mirabilis 14/18 (77.8%; 95% CI: 58.8–96.8), and Salmonella spp. 17/23 (73.9%; 95% CI: 55.9–91.9) (Table 4).

Table 4. Multidrug resistance profiles of Enterobacteriaceae isolates from chicken droppings in poultry farms at Gondar city, Northwest Ethiopia, March to June 2022.

Resistance pattern No. of antibiotics (classes) Type of isolate N
E. coli N = 87 K. pneumoniae N = 11 P. mirabilis N = 18 E. cloacae N = 4 Salmonella spp. N = 23 Total N = 143
Susceptible for all drug -- 4 - - - 3 7
TET 1 (1) 3 - - - 2 5
AMP 1 (1) 4 1 - - - 5
AMP TET 2 (2) 3 1 4 1 - 9
AMP SXT 2 (2) - - - - 1 1
AMP, TET, SXT 3 (3) 12 2 1 - 5 20
AMP, TET, NAL 3 (3) 11 - 1 - 3 15
AMP, TET, SXT, NAL 4 (4) 12 - - - 1 13
AMP, TET, SXT, CHL 4 (4) 2 - - - - 2
AMP, TET, NAL, CIP 4 (3) 5 - - - 1 6
AMP, TET, SXT, NAL, CIP 5 (4) - - 3 - 1 4
AMP, TET, SXT, NAL, CHL 5 (5) 8 1 1 - 1 11
AMP, TET, NAL, CIP, CXT 5 (4) 2 - - - - 2
AMP, TET, SXT, NAL, CIP, CHL 6 (5) 2 - - - - 2
AMP, TET, SXT, NAL, CHL, CXT 6 (6) 3 2 - - - 5
AMP, TET, SXT, NAL, CIP, CHL, CXT 7 (6) 1 - 4 - - 5
AMP, TET, SXT, NAL, CAZ CTX, CRO 7 (5) 4 1 - - 3 8
AMP, TET, SXT, NAL, CIP CXT, CAZ, CTX 8 (5) 2 1 1 2 1 7
AMP, TET, SXT, NAL, CIP, CHL, CAZ CTX, CRO, GEN, MER 9 (6) 6 2 3 - - 11
AMP, TET, SXT, NAL, CHL, CXT, CAZ CTX, CRO, GEN 9 (6) 1 - - 1 1 3
AMP, TET, SXT, NAL, CIP, CHL, CXT, CAZ CTX, CRO, GEN, MER 10 (6) 2 - - - - 2
Total non-MDR isolates N (%) -- 14 (16.1%) 2 (18.2%) 4 (22.2%) 1 (25.0%) 6 (26.1%) 27 (18.9%)
Total MDR isolates N (%) -- 73 (83.9%) 9 (81.8%) 14 (77.8%) 3 (75.0%) 17 (73.9%) 116 (81.1%)

Key: AMP = ampicillin; TET = tetracycline; SXT = trimethoprim-sulfamethoxazole; NAL = nalidixic acid; CHL = chloramphenicol; CIP = ciprofloxacin; CAZ = ceftazidime; CTX = cefotaxime, CRO = ceftriaxone; CXT = cefoxitin; GEN = gentamicin; MER = meropenem; MDR = multidrug-resistant (against ≥3 antimicrobial classes)

The prevalence of ESBL-producing Enterobacteriaceae

Among 143 bacterial isolates tested for ESBL, 12 (8.4%; CI: 3.9-12-9) were found to be positive. Of these, 11/87 (12.6%; 95% CI: 5.5–20.1) were E. coli and only one of the isolates was 1/11(9.1%; 95% CI: 1.5–27.3) K. pneumoniae.

Discussion

Antibiotic-resistant bacteria are a significant public health concern because the resistant bacteria and their mobile genetic elements disseminate among animals, humans, and the environment [25].

In this study, a total of 87 pooled chicken droppings were collected for bacteriological analysis and all of them were culture-positive. The culture-positivity rate in this study is in agreement with reports from Tanzania (100%) [26] and Indonesia (100%) [27]. However, it is higher than a study conducted in Jimma, Ethiopia 43.6% [28], Tanzania 55.2% [29], Egypt 12.5% and 25.6% [30, 31] Cameroon 44.1% [32], Nigeria 29.5% [33] and Albania 52.9% [34]. The difference in culture positivity rate may be due to the methods used to isolate the bacteria, the types of samples, and hygienic conditions in different places. In this study, for example, different types of samples were pooled, and most farms did not clean chicken droppings until a new flock was introduced, resulting in them being mixed with chicken feed, which fosters the cross-contamination of chickens [35].

In the current study, 143 Enterobacteriaceae isolates were identified, and the most predominant isolate was E. coli 87 (60.8%), followed by Salmonella spp. 23 (16.1%) and P. mirabilis 18 (12.6%). The same finding was also reported from Jimma, Ethiopia [28], Kenya [21], Nigeria [36], Côte d’Ivoire [20], and Malaysia [37]. The predominance of E. coli in this and many other studies may be because E. coli is a ubiquitous commensal bacterium that is predominantly found in the gastrointestinal tracts of animals and humans as a normal flora [38].

This study revealed that isolates from chicken droppings showed high resistance against ampicillin, tetracycline, and trimethoprim-sulfamethoxazole. This was also reported from Jimma, Ethiopia [28], Hawassa, Ethiopia [39], Tanzania [26, 29], Zambia [40], Cameroon [32], Côte d’Ivoire [20], Bangladesh [41], and Indonesia [42]. This demonstrates that these antibiotics are relatively cheap, easily accessible, and widely used antibiotics in the countries [43]. During farming, antibiotics are used for treatment or preventive purposes that favours the spread of ABR Enterobacteriaceae which can infect humans through the food chain [44]. In this study, these antibiotics were used in poultry for treatment or preventive purposes.

Moreover, the current study recorded higher resistance to quinolones like nalidixic acid 94 (65.7%) and ciprofloxacin 38 (26.6%). The use of quinolones for therapeutic purposes on the farm may be a possible contribution. The resistant pattern of Enterobacteriaceae in poultry to clinically important antibiotics in humans that are used for treating infections is a great concern [45]. For instance, in this study, enrofloxacin and ciprofloxacin are the most used antibiotics in poultry farms.

Bacterial isolates in the present study showed a relatively lower rate of resistance against meropenem 13 (9.1%) and gentamicin 16 (11.2%). This finding is supported by other studies, in Hawassa, Ethiopia [39], Kenya [21], and Albania [34]. Those studies reported 0% to 15% resistance for gentamicin and meropenem. Also, in Tanzania, gentamicin 10.3%, and 10.8% [26, 29], However, our result is lower than the studies conducted in Zambia, gentamicin 37.7% [40], Cameroon, meropenem 45% [32], Côte d’Ivoire, gentamicin 47.2% [20], Bangladesh, gentamicin 53% [41], and Indonesia, gentamicin 37% [27]. The possible explanation for a lower rate of resistance could be because of the inaccessibility of antibiotic agents that may not be given to poultry in the study area.

The prevalence of MDR E. coli in this study was 73 (83.9%). This finding is consistent with reports from Tanzania 86.8% [26], Zambia 85.7% [40], and Cameroon 83.1% [32] and lower than the study in Albania 95% [34], and in Malaysia 100% [37]. However, it is higher than a study conducted in Jimma, Ethiopia 54.2% [28], Tanzania 69.3% [29], and Egypt 57.8% [30]. This bacteria strain might be human pathogenic E. coli since, similar virulence factors with the same mechanism between avian pathogenic E. coli and human extra-intestinal pathogenic E. coli strains [46], and genetic similarity between E. coli involved in urinary tract infections in humans and those found in poultry and poultry products has been demonstrated [47].

The multidrug resistance rate of Salmonella spp. was 17 (73.9%). This is in agreement with a report from Debre Zeit, Ethiopia 86.0% [48], Albania 82% [34], and Malaysia 82% [37]. However, it is higher than a study conducted in Jimma, Ethiopia 44.4% [28]. This discrepancy could be due to the inappropriate use of antibiotics on the farms represents a selective pressure for resistant bacteria which can develop cross-resistance between several classes of antibiotics [49].

The prevalence of MDR K. pneumoniae, P. mirabilis, and E. cloacae in this study was 81.8%, 77.8%, and 75%, respectively. This is in line with the study conducted in Bangladesh P. mirabilis 83% [41]. However, these findings are higher than a study conducted in Jimma, Ethiopia, where 57.1% of K. pneumoniae and 50.0% of P. mirabilis reported as MDR [28], and 53.57% of K. pneumoniae was also reported as MDR by a study from Indonesia [42]. These bacteria may develop ABR via acquired mechanisms. The acquired resistance occurs through horizontal gene transfer such as conjugation, transduction, and transformation from other resistant bacteria. Additionally, mutations in the gene could also cause this MDR when the bacteria are constantly under pressure after being exposed to antibiotics [50].

The overall prevalence of MDR Enterobacteriaceae was 116 (81.1%; 95% CI: 74.7–87.5). This is higher than a report from Jimma, Ethiopia where the MDR prevalence was 52.5% [28]. This difference may be due to the types of commercial chicken, and the number of farms included in the study [51]. For instance, the present study includes multiple poultry farms and different types of commercial chickens such as layer, broiler, and day-old chickens.

In the present study, the ESBL-producing Enterobacteriaceae from chicken droppings was 8.4%, and the prevalence of ESBL-producing E. coli and K. pneumoniae was 12.6% and 9.1%, respectively. This finding is in line with the studies conducted in Uganda E. coli 17.5% [52], Egypt E. coli 12.5% [31], Tanzania E. coli 10.29% [26], India K. pneumoniae 5% [53], and Indonesia E. coli 7.03% [27], and it is lower than studies in Zambia E. coli 20.1% [40], Nigeria E. coli 37.8% [54], Ghana E. coli 29% [44]. In contrast, our result is higher than the study conducted in Tanzania E. coli 4.7% [29], India E. coli 5.3% [53], and Indonesia E. coli 3.3% [55]. This variation in prevalence rates could be the difference in ESBL screening methods used and it might be due to poor animal management practices and hygienic conditions; chicken dropping has contact with chicken feedings that enhance the spread of MDR bacteria in the flock [35].

Extended-spectrum beta-lactamase-producing E. coli and K. pneumoniae have been frequently reported in poultry and therefore poultry production might serve as a reservoir for ESBL-producing strains [56]. Different ESBL genes might exist and spread on various mobile genetic elements like plasmids that can transfer horizontally between bacterial species [57]. There is a significant association between the prevalence of ESBL and flock size (p = 0.014). The occurrence of ESBL increased with high flock size than the lower number of chickens on the farm. This finding is in agreement with the results of a study conducted in Uganda [52]. High flock size may increase stocking density which led to increased levels of airborne and respiratory disease transmission, thus increasing the risk of their environmental contamination with different bacterial strains. This is probably the cause of the reduced immune responses observed at high stocking densities, as high stocking density causes reduced feed consumption and lower growth rates. This leads to more susceptibility to ESBL-producing bacterial infection [58].

In this study, chickens aged less than two months were high risk to ESBL-producing Enterobacteriaceae carriage (p = 0.037). Because the gut normal flora of these birds is still maturing, making it easy for colonization by various pathogenic bacteria if they are exposed to the poultry environment. Additionally, due to their lower immunity, survival and multiplication of ingested ESBL-producing Enterobacteriaceae via the gastrointestinal tract is increased [59].

The occurrence of ESBL was significantly associated with the use of ciprofloxacin (p = 0.001) and trimethoprim-sulphadiazine (p = 0.018). This may be because the inappropriate use of these antibiotics in the farms represents a selective pressure for resistant bacteria which can develop cross-resistance between several classes of antibiotics like beta-lactam antibiotics [49]. In addition, these antibiotics were used for the treatment and prevent diseases in commercial farms in mass with crowded poultry flocks, these practices lead to a massive accumulation of antibiotics in the farm environment and facilitate the acquisition of resistance genes in bacteria coming in contact with them [60]. These bacteria are capable of being transmitted to humans through direct contact with infected birds and the consumption of contaminated food chains [15].

Limitations of the study

Isolation was performed on MacConkey and XLD agar which limits the isolation of fastidious Enterobacteriaceae and molecular characterization of the isolates wasn’t conducted.

Conclusions and recommendations

A high prevalence of clinically important bacterial pathogens with a high prevalence of MDR and ESBL-producing E. coli and K. pneumoniae were recovered in the present study. Poultry farms may be one potential reservoir for Enterobacteriaceae that shed into the environment through faecal matter contamination which might be a potential public health concern. Therefore, close supervision of poultry farms handling large flocks and day-old chickens should not be underestimated. The prudent use of antibiotics in poultry farms is better to be strictly supervised.

Supporting information

S1 File. Questionnaire English version.

(DOCX)

Acknowledgments

The authors would like to thank the Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, the University of Gondar. We also acknowledge Gondar city’s rural and urban agriculture centre and the poultry farm owners.

List of abbreviations

ABR

Antibiotics Resistance

AST

Antibiotic Susceptibility Testing

ATCC

American Type Culture Collection

BPW

Buffered Peptone Water

CLSI

Clinical and Laboratory Standards Institute

ESBL

Extended Spectrum Beta-Lactamase

MDR

Multidrug Resistance

Data Availability

All relevant data are within the manuscript and its Supporting Information files

Funding Statement

The authors have not received any specific funding for this work.

References

  • 1.Agyare C, Boamah VE, Zumbi CN, Osei FB. Antibiotic use in poultry production and its effects on bacterial resistance. Antimicrobial resistance-A global threat. 2018:1–20. [Google Scholar]
  • 2.Alemneh T, Getabalew M. Exotic chicken production performance, status and challenges in Ethiopia. Int J Vet Sci Res. 2019;5(2):039–45. [Google Scholar]
  • 3.Schar D, Sommanustweechai A, Laxminarayan R, Tangcharoensathien V. Surveillance of antimicrobial consumption in animal production sectors of low-and middle-income countries: Optimizing use and addressing antimicrobial resistance. PLoS medicine. 2018;15(3):e1002521. doi: 10.1371/journal.pmed.1002521 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in antimicrobial use in food animals. Proceedings of the National Academy of Sciences. 2015;112(18):5649–54. doi: 10.1073/pnas.1503141112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Landers TF, Cohen B, Wittum TE, Larson EL. A review of antibiotic use in food animals: perspective, policy, and potential. Public health reports. 2012;127(1):4–22. doi: 10.1177/003335491212700103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Besier R, Kahn L, Sargison N, Van Wyk J. Diagnosis, treatment and management of Haemonchus contortus in small ruminants. Advances in parasitology. 2016;93:181–238. doi: 10.1016/bs.apar.2016.02.024 [DOI] [PubMed] [Google Scholar]
  • 7.Phillips I, Casewell M, Cox T, de Groot B, Friis C, Jones R, et al. Does the use of antibiotics in food animals pose a risk to human health? A reply to critics. Journal of Antimicrobial Chemotherapy. 2004;54(1):276–8. [DOI] [PubMed] [Google Scholar]
  • 8.Kousar S, Rehman N, Javed A, Hussain A, Naeem M, Masood S, et al. Intensive Poultry Farming Practices Influence Antibiotic Resistance Profiles in Pseudomonas Aeruginosa Inhabiting Nearby Soils. Infection and Drug Resistance. 2021:4511–6. doi: 10.2147/IDR.S324055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.World Health Organization. Ten threats to global health in 2019 2019 [cited 2021 December 24]. Available from: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.
  • 10.O’Neill J. Tackling drug-resistant infections globally: final report and recommendations 2016 [cited 2022 February 16]. Available from: https://apo.org.au/sites/default/files/resource-files/2016-05/apo-nid63983.pdf.
  • 11.Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States 2019 [cited 2022 February 12]. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
  • 12.Saliu EM, Vahjen W, Zentek J. Types and prevalence of extended-spectrum beta-lactamase producing Enterobacteriaceae in poultry. Anim Health Res Rev. 2017;18(1):46–57. doi: 10.1017/S1466252317000020 [DOI] [PubMed] [Google Scholar]
  • 13.Saravanan M, Ramachandran B, Barabadi H. The prevalence and drug resistance pattern of extended spectrum β–lactamases (ESBLs) producing Enterobacteriaceae in Africa. Microbial pathogenesis. 2018;114:180–92. [DOI] [PubMed] [Google Scholar]
  • 14.Xu Y, Liu Y, Liu Y, Pei J, Yao S, Cheng C. Bacteriophage therapy against Enterobacteriaceae. Virol Sin. 2015;30(1):11–8. doi: 10.1007/s12250-014-3543-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.World Health Organization. Salmonella (non-typhoidal) 2018 [cited 2022 September 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/salmonella-(non-typhoidal).
  • 16.Ma F, Xu S, Tang Z, Li Z, Zhang L. Use of antimicrobials in food animals and impact of transmission of antimicrobial resistance on humans. Biosafety and Health. 2021;3(01):32–8. [Google Scholar]
  • 17.Hedman HD, Vasco KA, Zhang L. A review of antimicrobial resistance in poultry farming within low-resource settings. Animals. 2020;10(8):1264. doi: 10.3390/ani10081264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mouiche MMM, Moffo F, Akoachere JTK, Okah-Nnane NH, Mapiefou NP, Ndze VN, et al. Antimicrobial resistance from a one health perspective in Cameroon: a systematic review and meta-analysis. BMC Public Health. 2019;19(1):1135. doi: 10.1186/s12889-019-7450-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.World Population Review. Gondar Population 2022 2022 [cited 2022 Februay 12]. Available from: https://worldpopulationreview.com/world-cities/gondar-population.
  • 20.Assoumy MA, Bedekelabou AP, Teko-Agbo A, Ossebi W, Akoda K, Nimbona F, et al. Antibiotic resistance of Escherichia coli and Salmonella spp. strains isolated from healthy poultry farms in the districts of Abidjan and Agnibilékrou (Côte d’Ivoire). Veterinary World. 2021;14(4):1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Langata LM, Maingi JM, Musonye HA, Kiiru J, Nyamache AK. Antimicrobial resistance genes in Salmonella and Escherichia coli isolates from chicken droppings in Nairobi, Kenya. BMC research notes. 2019;12(1):1–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Cheesbrough M. District laboratory practice in tropical countries, part 2: Cambridge university press; 2006. [Google Scholar]
  • 23.Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed. CLSI. supplement. M100 2021 [cited 2021 February 24]. Available from: https://www.treata.academy/wp-content/uploads/2021/03/CLSI-31-2021.pdf.
  • 24.Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clinical microbiology and infection. 2012;18(3):268–81. doi: 10.1111/j.1469-0691.2011.03570.x [DOI] [PubMed] [Google Scholar]
  • 25.Robinson TP, Bu D, Carrique-Mas J, Fèvre EM, Gilbert M, Grace D, et al. Antibiotic resistance is the quintessential One Health issue. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2016;110(7):377–80. doi: 10.1093/trstmh/trw048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kiiti RW, Komba EV, Msoffe PL, Mshana SE, Rweyemamu M, Matee MIN. Antimicrobial Resistance Profiles of Escherichia coli Isolated from Broiler and Layer Chickens in Arusha and Mwanza, Tanzania. International Journal of Microbiology. 2021;21:9. doi: 10.1155/2021/6759046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Effendi MH, Tyasningsih W, Yurianti YA, Rahmahani J, Harijani N, Plumeriastuti H. Presence of multidrug resistance (MDR) and extended-spectrum beta-lactamase (ESBL) of Escherichia coli isolated from cloacal swab of broilers in several wet markets in Surabaya, Indonesia. Biodiversitas Journal of Biological Diversity. 2021;22(1). [Google Scholar]
  • 28.Atnafu Bushen ET, Abayneh M. Drug-and Multidrug-Resistance Pattern of Enterobacteriaceae Isolated from Droppings of Healthy Chickens on a Poultry Farm in Southwest Ethiopia. Infection and drug resistance. 2021;14:2051. doi: 10.2147/IDR.S312185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Mgaya FX, Matee MI, Muhairwa AP, Hoza AS. Occurrence of multidrug resistant Escherichia coli in raw meat and cloaca swabs in poultry processed in slaughter slabs in Dar es Salaam, Tanzania. Antibiotics. 2021;10(4):343. doi: 10.3390/antibiotics10040343 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.AbdelRahman MAA, Roshdy H, Samir AH, Hamed EA. Antibiotic resistance and extended-spectrum beta-lactamase in Escherichia coli isolates from imported 1-day-old chicks, ducklings, and turkey poults. Vet World. 2020;13(6):1037–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Moawad AA, Hotzel H, Neubauer H, Ehricht R, Monecke S, Tomaso H, et al. Antimicrobial resistance in Enterobacteriaceae from healthy broilers in Egypt: emergence of colistin-resistant and extended-spectrum β-lactamase-producing Escherichia coli. Gut pathogens. 2018;10(1):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Moffo F, Mouiche MMM, Djomgang HK, Tombe P, Wade A, Kochivi FL, et al. Poultry litter contamination by Escherichia coli resistant to critically important antimicrobials for human and animal use and risk for public health in cameroon. Antibiotics. 2021;10(4):402. doi: 10.3390/antibiotics10040402 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Olonitola OS, Fahrenfeld N, Pruden A. Antibiotic resistance profiles among mesophilic aerobic bacteria in Nigerian chicken litter and associated antibiotic resistance genes. Poultry science. 2015;94(5):867–74. [DOI] [PubMed] [Google Scholar]
  • 34.Alcaine S, Molla L, Nugen S, Kruse H. Results of a pilot antibiotic resistance survey of Albanian poultry farms. Journal of global antimicrobial resistance. 2016;4:60–4. doi: 10.1016/j.jgar.2015.11.003 [DOI] [PubMed] [Google Scholar]
  • 35.Ngai DG, Nyamache AK, Ombori O. Prevalence and antimicrobial resistance profiles of Salmonella species and Escherichia coli isolates from poultry feeds in Ruiru Sub-County, Kenya. BMC research notes. 2021;14(1):1–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Omoya F, Ajayi K. Antibiotic resistance pattern of pathogenic bacteria isolated from poultry droppings in Akure, Nigeria. Futa Journal of Research in Sciences. 2016;12(2):219–27. [Google Scholar]
  • 37.Ibrahim S, Wei Hoong L, Lai Siong Y, Mustapha Z, CW Zalati CS, Aklilu E, et al. Prevalence of antimicrobial resistance (AMR) Salmonella spp. and Escherichia coli isolated from broilers in the East Coast of Peninsular Malaysia. Antibiotics. 2021;10(5):579. doi: 10.3390/antibiotics10050579 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Torres AG, Arenas-Hernández MM, Martínez-Laguna Y. Overview of Escherichia coli. Pathogenic Escherichia coli in latin America; 2010. p. 1–7. [Google Scholar]
  • 39.Abdi RD, Mengstie F, Beyi AF, Beyene T, Waktole H, Mammo B, et al. Determination of the sources and antimicrobial resistance patterns of Salmonella isolated from the poultry industry in Southern Ethiopia. BMC infectious diseases. 2017;17(1):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Chishimba K, Hang’ombe BM, Muzandu K, Mshana SE, Matee MI, Nakajima C, et al. Detection of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Market-Ready Chickens in Zambia. International Journal of Microbiology. 2016;16:52. doi: 10.1155/2016/5275724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Nahar A, Siddiquee M, Nahar S, Anwar KS, Islam S. Multidrug resistant-proteus mirabilis isolated from chicken droppings in commercial poultry farms: Bio-security concern and emerging public health threat in Bangladesh. Journal of Biosafety & Health Education. 2014;16(2):1–37. [Google Scholar]
  • 42.Permatasari DA, Witaningrum AM, Wibisono FJ, Effendi MH. Detection and prevalence of multidrug-resistant Klebsiella pneumoniae strains isolated from poultry farms in Blitar, Indonesia. Biodiversitas Journal of Biological Diversity. 2020;21(10). [Google Scholar]
  • 43.Kimera ZI, Mshana SE, Rweyemamu MM, Mboera LE, Matee MI. Antimicrobial use and resistance in food-producing animals and the environment: an African perspective. Antimicrobial Resistance & Infection Control. 2020;9(1):1–12. doi: 10.1186/s13756-020-0697-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Falgenhauer L, Imirzalioglu C, Oppong K, Akenten CW, Hogan B, Krumkamp R, et al. Detection and characterization of ESBL-producing Escherichia coli from humans and poultry in Ghana. Frontiers in microbiology. 2019;9:3358. doi: 10.3389/fmicb.2018.03358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Nguyen VT, Carrique-Mas JJ, Ngo TH, Ho HM, Ha TT, Campbell JI, et al. Prevalence and risk factors for carriage of antimicrobial-resistant Escherichia coli on household and small-scale chicken farms in the Mekong Delta of Vietnam. Journal of Antimicrobial Chemotherapy. 2015;70(7):2144–52. doi: 10.1093/jac/dkv053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Najafi S, Rahimi M, Nikousefat Z. Extra intestinal pathogenic Escherichia coli from human and avian origin: Detection of the most common virulence-encoding genes. Veterinary Research Forum. 2019;10(1):43–9. doi: 10.30466/vrf.2019.34307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Sarowska J, Olszak T, Jama-Kmiecik A, Frej-Madrzak M, Futoma-Koloch B, Gawel A, et al. Comparative Characteristics and Pathogenic Potential of Escherichia coli Isolates Originating from Poultry Farms, Retail Meat, and Human Urinary Tract Infection. Life. 2022;12(6):845. doi: 10.3390/life12060845 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Asfaw Ali D, Tadesse B, Ebabu A. Prevalence and Antibiotic Resistance Pattern of Salmonella Isolated from Caecal Contents of Exotic Chicken in Debre Zeit and Modjo, Ethiopia. International Journal of Microbiology. 2020;20:1–6. doi: 10.1155/2020/1910630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Chantziaras I. Epidemiology of antimicrobial resistance in commensal E. coli: focus on selection and spread of fluoroquinolone resistance in broilers. Ghent University. 2017;12(2):122. [Google Scholar]
  • 50.Tenover FC. Mechanisms of antimicrobial resistance in bacteria. The American journal of medicine. 2006;119(6):3–10. [DOI] [PubMed] [Google Scholar]
  • 51.Daehre K, Projahn M, Semmler T, Roesler U, Friese A. Extended-spectrum beta-lactamase-/AmpC beta-lactamase-producing Enterobacteriaceae in broiler farms: transmission dynamics at farm level. Microbial Drug Resistance. 2018;24(4):511–8. doi: 10.1089/mdr.2017.0150 [DOI] [PubMed] [Google Scholar]
  • 52.Kakooza S, Munyiirwa D, Ssajjakambwe P, Kayaga E, Tayebwa DS, Ndoboli D, et al. Epidemiological Dynamics of Extended-Spectrum β-Lactamase- or AmpC β-Lactamase-Producing Escherichia coli Screened in Apparently Healthy Chickens in Uganda. Scientifica. 2021;21:32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Bhardwaj K, Shenoy S, Baliga S, Unnikrishnan B, Baliga BS, Shetty VK. Research Note: Characterization of antibiotic resistant phenotypes and linked genes of Escherichia coli and Klebsiella pneumoniae from healthy broiler chickens, Karnataka, India. Poultry Science. 2021;100(6):101094. doi: 10.1016/j.psj.2021.101094 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Aworh MK, Kwaga J, Okolocha E, Harden L, Hull D, Hendriksen RS, et al. Extended-spectrum ß-lactamase-producing Escherichia coli among humans, chickens and poultry environments in Abuja, Nigeria. One Health Outlook. 2020;2(1):1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Wibisono FJ, Sumiarto B, Untari T, Effendi MH, Permatasari DA, Witaningrum AM. The presence of extended-spectrum beta-lactamase (ESBL) producing scherichia coli on layer chicken farms in Blitar Area, Indonesia. Biodiversitas. 2020;21(6):2667–71. [Google Scholar]
  • 56.Mikhayel M, Leclercq SO, Sarkis DK, Doublet B. Occurrence of the Colistin resistance gene mcr-1 and additional antibiotic resistance genes in ESBL/AmpC-producing Escherichia coli from poultry in Lebanon: A nationwide survey. Microbiology Spectrum. 2021;9(2):25–1. doi: 10.1128/Spectrum.00025-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clinical microbiology reviews. 2018;31(4):88–17. doi: 10.1128/CMR.00088-17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Bilal RM, Hassan F-u, Farag MR, Nasir TA, Ragni M, Mahgoub HA, et al. Thermal stress and high stocking densities in poultry farms: Potential effects and mitigation strategies. Journal of Thermal Biology. 2021;99:102944. doi: 10.1016/j.jtherbio.2021.102944 [DOI] [PubMed] [Google Scholar]
  • 59.Kers JG, Velkers FC, Fischer EA, Hermes GD, Stegeman JA, Smidt H. Host and environmental factors affecting the intestinal microbiota in chickens. Frontiers in microbiology. 2018;9:235. doi: 10.3389/fmicb.2018.00235 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Allen HK. Antibiotic resistance gene discovery in food-producing animals. Current Opinion in Microbiology. 2014;19:25–9. doi: 10.1016/j.mib.2014.06.001 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Md Tanvir Rahman

13 Apr 2023

PONE-D-23-06358Multidrug-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated from chicken droppings in poultry farms at Gondar city, Northwest EthiopiaPLOS ONE

Dear Dr. Tigabie,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 28 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Md. Tanvir Rahman, DVM, MSc, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Additional Editor Comments (if provided):

Dear Authors,

Please see the comments of the reviewers and take the necessary actions.

Best wishes,

Tanvir

==

Prof. Md. Tanvir Rahman

DVM, MSc (Canada), Ph.D. (UK), Postdoc (Germany)

Department of Microbiology and Hygiene,

Faculty of Veterinary Science,

Bangladesh Agricultural University,

Mymensingh-2202, Bangladesh.

Phone. + 88-01913323307; Fax + 88-09161510

E.mail: tanvirahman@bau.edu.bd

http://vmh.bau.edu.bd/profile/VMH1005

https://orcid.org/0000-0001-5432-480X

https://sites.google.com/site/tanvirahman/Home

https://www.researchgate.net/profile/DrMdTanvir_Rahman/research

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. There are many places in the manuscript written wrongly used words, phrases and sentences. The English correction is needed for sentence to sentence.

2. The theme of the abstract is not highlighted/reflected to emphasize the title. Please modify the abstract with noting a brief primary objective.

3. The Introduction section is very weak and uninformative. Please strengthen the introduction with relevant citations. There is so much languages problem. Please modify it by Native English Speaker. What is the significance of the study? How is the study different from others?…….Please note it down and rectify accordingly?

4. Results and discussion portion is haphazardly written and difficult to correlate with each other. Please modify the discussion in systemic manner with relevant references. Please modify the discussion by strengthening the results. There is also lacuna of the representation of the discussion in the present endeavor. Please modify the discussion with proper justification and analysis by strengthening the novelty of the work.

Reviewer #2: Abstract

While the author aimed to Enterobacteriaceae, they have mentioned only enrichment and isolation of Salmonella.

They said isolation of E. coli, Salmonella and P. mirabilis. But, just next to that they mentioned 9.1% of K. pneumonia as ESBL!! Strange, why didn’t they mention K. pneumonia earlier?

Introduction

The importance is nicely described with necessary references; however, this could be further improved with information on ESBL.

Few typo mistakes.

Materials and methods

Although they targeted Enterobacteriaceae, isolation was performed on MacConkey and XLD agar which limits the isolation of other enterobacteriae and increasing the chance of missing bacteria that does not grow on those media properly. So, my suggestion is, instead of saying Enterobacteriaceae, they could mention specific bacteria like E. coli and Salmonella…

Isolation techniques are not properly described.

The authors didn’t mention, how they calculated sample size, i.e. no sample size calculation was performed!!

Line 158: 5%???

Results

Nicely presented with easy going Tables.

In Prevalence, they didn’t mention about K. pneumonia, although it’s prevalence was not that low. I think it worth to mention in the prevalence section. In addition, they also isolated E. cloacae, but no mention in the prevalence or isolation section (Table 4)

But, in Antibiotic resistance K. pneumonia suddenly came (Table 3)!!

Discussion

The authors have discussed the findings nicely with evidences from different part of the world. However, the authors have identified several general characteristics significantly associated with the occurrence of ESBL, but they didn’t discussion anything about them.

The discussion feels very monotonous. It could be improved with suggestion from a person with good English writing skill.

Conclusion and recommendations

Waste disposal was not significantly associated with occurrence of ESBL according to their findings (Table 1). Rather, some critical factors were identified, which could be highlighted in the conclusion section.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Jayedul Hassan

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 9;18(6):e0287043. doi: 10.1371/journal.pone.0287043.r002

Author response to Decision Letter 0


17 May 2023

PONE-D-23-06358

Multidrug-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated from chicken droppings in poultry farms at Gondar city, Northwest Ethiopia

PLOS ONE

Dear Dr. Tigabie,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 28 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Md. Tanvir Rahman, DVM, MSc, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Additional Editor Comments (if provided):

Dear Authors,

Please see the comments of the reviewers and take the necessary actions.

Best wishes,

Tanvir

==

Prof. Md. Tanvir Rahman

DVM, MSc (Canada), Ph.D. (UK), Postdoc (Germany)

Department of Microbiology and Hygiene,

Faculty of Veterinary Science,

Bangladesh Agricultural University,

Mymensingh-2202, Bangladesh.

Phone. + 88-01913323307; Fax + 88-09161510

E.mail: tanvirahman@bau.edu.bd

http://vmh.bau.edu.bd/profile/VMH1005

https://orcid.org/0000-0001-5432-480X

https://sites.google.com/site/tanvirahman/Home

https://www.researchgate.net/profile/DrMdTanvir_Rahman/research

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. There are many places in the manuscript written wrongly used words, phrases and sentences. The English correction is needed for sentence to sentence.

2. The theme of the abstract is not highlighted/reflected to emphasize the title. Please modify the abstract with noting a brief primary objective.

3. The Introduction section is very weak and uninformative. Please strengthen the introduction with relevant citations. There is so much languages problem. Please modify it by Native English Speaker. What is the significance of the study? How is the study different from others?…….Please note it down and rectify accordingly?

4. Results and discussion portion is haphazardly written and difficult to correlate with each other. Please modify the discussion in systemic manner with relevant references. Please modify the discussion by strengthening the results. There is also lacuna of the representation of the discussion in the present endeavor. Please modify the discussion with proper justification and analysis by strengthening the novelty of the work.

Reviewer #2: Abstract

While the author aimed to Enterobacteriaceae, they have mentioned only enrichment and isolation of Salmonella.

They said isolation of E. coli, Salmonella and P. mirabilis. But, just next to that they mentioned 9.1% of K. pneumonia as ESBL!! Strange, why didn’t they mention K. pneumonia earlier?

Introduction

The importance is nicely described with necessary references; however, this could be further improved with information on ESBL.

Few typo mistakes.

Materials and methods

Although they targeted Enterobacteriaceae, isolation was performed on MacConkey and XLD agar which limits the isolation of other enterobacteriae and increasing the chance of missing bacteria that does not grow on those media properly. So, my suggestion is, instead of saying Enterobacteriaceae, they could mention specific bacteria like E. coli and Salmonella…

Isolation techniques are not properly described.

The authors didn’t mention, how they calculated sample size, i.e. no sample size calculation was performed!!

Line 158: 5%???

Results

Nicely presented with easy going Tables.

In Prevalence, they didn’t mention about K. pneumonia, although it’s prevalence was not that low. I think it worth to mention in the prevalence section. In addition, they also isolated E. cloacae, but no mention in the prevalence or isolation section (Table 4)

But, in Antibiotic resistance K. pneumonia suddenly came (Table 3)!!

Discussion

The authors have discussed the findings nicely with evidences from different part of the world. However, the authors have identified several general characteristics significantly associated with the occurrence of ESBL, but they didn’t discussion anything about them.

The discussion feels very monotonous. It could be improved with suggestion from a person with good English writing skill.

Conclusion and recommendations

Waste disposal was not significantly associated with occurrence of ESBL according to their findings (Table 1). Rather, some critical factors were identified, which could be highlighted in the conclusion section.

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Jayedul Hassan

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Md Tanvir Rahman

30 May 2023

Multidrug-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated from chicken droppings in poultry farms at Gondar city, Northwest Ethiopia

PONE-D-23-06358R1

Dear Dr. Tigabie,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Md. Tanvir Rahman, DVM, MSc, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thanks for addressing the comments of the reviewers and revising the manuscrot.

Reviewers' comments:

Acceptance letter

Md Tanvir Rahman

2 Jun 2023

PONE-D-23-06358R1

Multidrug-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae isolated from chicken droppings in poultry farms at Gondar City, Northwest Ethiopia

Dear Dr. Tigabie:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Professor Md. Tanvir Rahman

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Questionnaire English version.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES